DexCom, Inc.

Informe Stock NasdaqGS:DXCM

Capitalización de mercado: US$52.6b

Dividendos de DexCom

Dividendo controles de criterios 0/6

DexCom no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria1.8%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Beneficios por acciónUS$1.40
Rentabilidad por dividendo prevista a 3 años0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25
DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21
Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24
What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend

Sep 21

DexCom promotes technology chief Leach to COO

Aug 31

DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

Aug 01
DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

DexCom stock down ~7% after hours as Q2 results miss expectations

Jul 28

Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

Jul 13
Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

DexCom: I Wouldn't Buy The Dip

Jul 07

Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Jun 24
Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Jun 03
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom: Q1'22 Earnings Strong Enough To Maintain Valuation But Not To Increase It

May 01

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Apr 12
DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de DXCM han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de DXCM han aumentado.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de DexCom vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de DXCM con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (DXCM)n/a
Suelo de mercado 25% (US)1.6%
Techo de mercado 25% (US)4.9%
Media de la industria (Medical Equipment)1.8%
Previsión de analistas en 3 años (DXCM)0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de DXCM en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de DXCM en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.


Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de DXCM para determinar si sus dividendos están cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que DXCM no ha comunicado ningún pago.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target